Genuv

Founded in 2016 in South Korea, Genuv() is a clinical-stage biopharma that specializes in discovering and developing innovative therapeutics based on own platform technologies for drug discovery. GENUV is dedicated to the discovery and development of life-transforming therapeutics for patients with debilitating diseases. To do this, we passionately endeavor to advance our own platform technologies and capitalize on our strengths in multi-disciplinary collaborations with external partners. Our current research and development focus is on a) small molecule drugs to treat neurodegenerative diseases through neurogenesis and neural homeostasis and b) antibody drugs for immuno-oncology treatment

Ip strategy,human antibody mouse platform,neural stem cell based drug screening platform,moa: neurogenesis & neural homeostasis,alzheimer's diseases,als,immuno-neurology,immuno-oncology,antibody drug,drug discovery & development,platform-based drug develompent,and early stage r&d

Genuv operates in the Biotechnology industry.

Genuv's revenue is 11m - 100m

Genuv has 11 - 50 employees.